MCID: PST022
MIFTS: 41

Posterior Uveal Melanoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Posterior Uveal Melanoma

MalaCards integrated aliases for Posterior Uveal Melanoma:

Name: Posterior Uveal Melanoma 12 15
Ciliary Body and Choroid Melanoma, Medium/large Size 70
Ciliary Body and Choroid Melanoma, Small Size 70
Medium/large Size Posterior Uveal Melanoma 12
Small Size Posterior Uveal Melanoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6566
NCIt 50 C9089 C9090
UMLS 70 C0278867 C0278868

Summaries for Posterior Uveal Melanoma

MalaCards based summary : Posterior Uveal Melanoma, also known as ciliary body and choroid melanoma, medium/large size, is related to melanoma, uveal and melanoma. An important gene associated with Posterior Uveal Melanoma is MIR182 (MicroRNA 182), and among its related pathways/superpathways are Human cytomegalovirus infection and PI3K-Akt signaling pathway. The drugs Melphalan and Fotemustine have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Posterior Uveal Melanoma

Diseases in the Melanoma, Uveal family:

Melanoma, Uveal 1 Melanoma, Uveal 2
Posterior Uveal Melanoma

Diseases related to Posterior Uveal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 melanoma, uveal 31.0 VEGFA THBS1 MITF BRAF
2 melanoma 30.0 VEGFA THBS1 MITF MIR182 BRAF BCL2
3 skin melanoma 29.8 VEGFA MITF BRAF
4 neovascular glaucoma 10.5
5 retinal detachment 10.4
6 ocular melanoma 10.4
7 cataract 10.2
8 optic nerve disease 10.2
9 macular retinal edema 10.2
10 macular holes 10.2
11 chromosomal triplication 10.2
12 nodular malignant melanoma 10.1 MITF BRAF
13 melanoma, cutaneous malignant 1 10.0
14 retinoblastoma 10.0
15 vitreoretinopathy, neovascular inflammatory 10.0
16 3-methylglutaconic aciduria, type iii 10.0
17 retinoschisis 1, x-linked, juvenile 10.0
18 microvascular complications of diabetes 5 10.0
19 bullous keratopathy 10.0
20 scleritis 10.0
21 keratopathy 10.0
22 hemangioma 10.0
23 malignant choroid melanoma 10.0
24 malignant ciliary body melanoma 10.0
25 neurofibromatosis 10.0
26 47,xyy 10.0
27 vitreoretinopathy 10.0
28 amelanotic melanoma 10.0 THBS1 BRAF
29 soft tissue sarcoma 10.0 VEGFA BCL2
30 nodular goiter 10.0 VEGFA BRAF
31 chronic mountain sickness 10.0 VEGFA BCL2
32 acute chest syndrome 10.0 VEGFA THBS1
33 colorectal adenocarcinoma 9.9 VEGFA MIR182 BRAF
34 mucosal melanoma 9.9 VEGFA MITF BRAF
35 renal cell carcinoma, papillary, 1 9.9 VEGFA MITF BRAF
36 primary mediastinal b-cell lymphoma 9.9 BRAF BCL2
37 vascular cancer 9.9 VEGFA THBS1 MITF
38 anaplastic astrocytoma 9.8 VEGFA THBS1 CCND2
39 retinal ischemia 9.8 VEGFA BCL2
40 immunodeficiency by defective expression of mhc class i 9.8 TAP2 TAP1
41 malignant astrocytoma 9.8 VEGFA THBS1 BRAF
42 alveolar echinococcosis 9.8 TAP2 TAP1
43 suppressor of tumorigenicity 3 9.8 TAP1 BCL2
44 cholangiocarcinoma 9.8 VEGFA THBS1 BRAF
45 ovarian serous cystadenocarcinoma 9.8 VEGFA BRAF BCL2
46 bare lymphocyte syndrome, type i 9.7 TAP2 TAP1
47 mantle cell lymphoma 9.7 VEGFA CCND2 BCL2
48 idiopathic bronchiectasis 9.7 TAP2 TAP1
49 breast ductal carcinoma 9.7 VEGFA THBS1 BCL2
50 lymphoma, non-hodgkin, familial 9.7 MIR182 CCND2 BRAF BCL2

Graphical network of the top 20 diseases related to Posterior Uveal Melanoma:



Diseases related to Posterior Uveal Melanoma

Symptoms & Phenotypes for Posterior Uveal Melanoma

GenomeRNAi Phenotypes related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.75 BCL2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.75 CCND2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-109 9.75 CCND2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.75 BCL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.75 TAP2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.75 TAP2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.75 BCL2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.75 BCL2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.75 CCND2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.75 BCL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.75 BCL2 TAP2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.75 TAP2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.75 TAP2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.75 BCL2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.75 TAP2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.75 BCL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.75 BCL2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.75 TAP2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.75 BCL2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.75 BCL2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.75 CCND2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.75 BCL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.75 CCND2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.75 BCL2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.75 CCND2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.75 BCL2

MGI Mouse Phenotypes related to Posterior Uveal Melanoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 BCL2 BRAF CCND2 MITF TAP1 TAP2
2 cardiovascular system MP:0005385 9.98 BCL2 BRAF CCND2 TAP1 THBS1 THBS2
3 immune system MP:0005387 9.97 BCL2 BRAF CCND2 MITF TAP1 TAP2
4 craniofacial MP:0005382 9.8 BCL2 BRAF CCND2 MITF VEGFA
5 integument MP:0010771 9.8 BCL2 BRAF MITF TAP1 THBS1 THBS2
6 limbs/digits/tail MP:0005371 9.55 BRAF MITF THBS1 THBS2 VEGFA
7 neoplasm MP:0002006 9.43 BCL2 BRAF TAP1 THBS1 THBS2 VEGFA
8 vision/eye MP:0005391 9.1 BCL2 BRAF CCND2 MITF THBS1 VEGFA

Drugs & Therapeutics for Posterior Uveal Melanoma

Drugs for Posterior Uveal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Melphalan Approved Phase 3 148-82-3 4053 460612
2
Fotemustine Investigational Phase 3 92118-27-9
3 Alkylating Agents Phase 3
4 Immunosuppressive Agents Phase 3
5 Vaccines Phase 3
6 Liver Extracts Phase 3
7
Bevacizumab Approved, Investigational Phase 2 216974-75-3
8
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
9
Sodium citrate Approved, Investigational Phase 2 68-04-2
10
Tamoxifen Approved Phase 2 10540-29-1 2733526
11
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
12
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
13
Thalidomide Approved, Investigational, Withdrawn Phase 1, Phase 2 50-35-1 5426
14
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
15
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
16
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
17
Aluminum sulfate Approved Phase 2 10043-01-3
18
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
19
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
20
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166 2942
21
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
22
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
23
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
24
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
25
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
26
Iodine Approved, Investigational Phase 2 7553-56-2 807
27
Acetaminophen Approved Phase 2 103-90-2 1983
28
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
29
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
31
Promethazine Approved, Investigational Phase 2 60-87-7 4927
32
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
33
Lenalidomide Approved Phase 2 191732-72-6 216326
34
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
36
Molgramostim Investigational Phase 2 99283-10-0
37
Cadexomer iodine Experimental Phase 2 94820-09-4
38 Hormone Antagonists Phase 2
39 Estrogen Antagonists Phase 2
40 Citrate Phase 2
41 Estrogen Receptor Antagonists Phase 2
42 Hormones Phase 2
43 Estrogens Phase 2
44 Estrogen Receptor Modulators Phase 2
45 Antineoplastic Agents, Hormonal Phase 2
46 Adjuvants, Immunologic Phase 2
47 Immunologic Factors Phase 2
48 Freund's Adjuvant Phase 2
49 Anti-Infective Agents Phase 1, Phase 2
50 Anti-Retroviral Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
2 Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse Terminated NCT00036816 Phase 3
3 Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
4 Phase II Single-Center Study of Bevacizumab in Combination With Temozolomide in Patients With First-Line Metastatic Uveal Melanoma Unknown status NCT01217398 Phase 2 temozolomide
5 A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
6 MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2
7 An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
8 A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
9 A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
10 A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
11 A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma Completed NCT00031733 Phase 2 alum adjuvant
12 A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma Completed NCT00738361 Phase 2 nab-paclitaxel
13 A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
14 Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma Completed NCT00238329 Phase 2 thalidomide
15 An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
16 Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma Completed NCT00089219 Phase 1, Phase 2
17 Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma Completed NCT00089206 Phase 2
18 Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma Completed NCT00085306 Phase 2
19 Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance Completed NCT01100528 Phase 2 dacarbazine
20 Phase II Study of IMC-A12 in Metastatic Uveal Melanoma Completed NCT01413191 Phase 2
21 A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for the Treatment of Metastatic Melanoma Completed NCT00288041 Phase 2 carboplatin;paclitaxel;bortezomib
22 A PHASE II TRIAL OF A VACCINE COMBINING MULTIPLE CLASS I PEPTIDES WITH MONTANIDE ISA 51 OR ISA 51 VG AND CpG ADJUVANT 7909 FOR PATIENTS WITH RESECTED STAGES IIC/III AND IV MELANOMA Completed NCT00085189 Phase 2 Montanide ISA 51 VG;agatolimod sodium
23 A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma Completed NCT00450255 Phase 2
24 Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
25 A Phase II Study of Vorinostat in Patients With Advanced Melanoma Completed NCT00121225 Phase 2 vorinostat
26 A Randomized Phase II Continuation Booster Trial After A Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 and ISA 51 VG With Or Without GM-CSF For Patients With Resected Stages IIB/C, III And IV Melanoma Completed NCT00089063 Phase 2 Montanide ISA 51 VG
27 A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma Recruiting NCT02068586 Phase 2 Sunitinib;Valproic Acid
28 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
29 A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma Terminated NCT00482911 Phase 2 cyclophosphamide;lenalidomide;sunitinib malate
30 A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment Completed NCT00705640 Phase 1
31 Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Mouse gp100 DNA: A Pilot Study to Compare Intramuscular Jet Injection With Particle Mediated Delivery Completed NCT00398073 Phase 1
32 An Open-label Study Of MDX-CTLA4 In Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Resected Stage III Or Stage IV Melanoma Completed NCT00025181 Phase 1
33 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
34 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat
35 A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma Completed NCT01005472 Phase 1 sunitinib malate;temozolomide
36 A Dose Ranging Trial of MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Using Cytokines With Autologous Lymphocyte Infusion With or Without Escalating Doses of Fludarabine for Patients With Chemotherapy-naive Metastatic Melanoma Completed NCT00313508 Phase 1 Fludarabine
37 Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
38 Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma Completed NCT00471471 Phase 1
39 A Phase I Trial of a Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 With ProGP for Patients With Resected Stages III and IV Melanoma Terminated NCT00005841 Phase 1
40 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
41 Prognostication of Uveal Melanoma by Fine Needle Aspiration (FNA) and Fluorescence in Situ Hybridization (FlSH) Completed NCT00952939
42 Evaluation of the Detection of Tumor Cells in Bone Marrow and Blood in Patients With Choroid Melanoma Completed NCT00897624
43 Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide
44 Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver Terminated NCT01730157 Early Phase 1
45 Validation of a Molecular Test for Predicting Metastasis in Patients With Uveal Melanoma Withdrawn NCT00406120

Search NIH Clinical Center for Posterior Uveal Melanoma

Genetic Tests for Posterior Uveal Melanoma

Anatomical Context for Posterior Uveal Melanoma

MalaCards organs/tissues related to Posterior Uveal Melanoma:

40
Eye, Liver, Endothelial, Bone Marrow, Breast, Skin, T Cells

Publications for Posterior Uveal Melanoma

Articles related to Posterior Uveal Melanoma:

(show top 50) (show all 183)
# Title Authors PMID Year
1
Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70-year nationwide cohort. 61
33738986 2021
2
Cost-utility analysis of a decade of liver screening for metastases using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO). 61
33516960 2021
3
Long-term results of visual function in posterior uveal melanoma patients treated with I125 episcleral brachytherapy in a Spanish referral Ocular Oncology Unit. 61
33567036 2021
4
Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing. 61
33396957 2020
5
Posterior uveal melanoma in 321 Asian Indian patients: analysis based on the 8th edition of American Joint Committee Cancer classification. 61
32601966 2020
6
Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. 61
32718045 2020
7
Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter? 61
32081600 2020
8
Indications for Fine Needle Aspiration Biopsy of Posterior Segment Intraocular Tumors. 61
31170388 2019
9
DIAGNOSTIC CHALLENGES IN NECROTIC UVEAL MELANOMA. 61
31425450 2019
10
Iodine-125 Episcleral Plaque Brachytherapy for AJCC T4 Posterior Uveal Melanoma: Clinical Outcomes in 158 Patients. 61
31559245 2019
11
Survival of Young Patients With Posterior Uveal Melanoma. 61
31318400 2019
12
Survival of Young Patients With Posterior Uveal Melanoma-Reply. 61
31318399 2019
13
Melanoma-Associated Spongiform Scleropathy Adjacent to a Choroidal Nevus. 61
31367587 2019
14
Endoresection utilizing pars plana vitrectomy for benign and malignant intraocular tumors. 61
30883440 2019
15
Clinical Features, Metastasis, and Survival in Patients Younger Than 21 Years With Posterior Uveal Melanoma. 61
30422230 2019
16
Clinical implications of biopsy for posterior uveal melanoma. 61
31664321 2019
17
INTRAVITREAL DEXAMETHASONE (OZURDEX) IMPLANT FOR RADIATION MACULOPATHY SECONDARY TO STEREOTACTIC RADIOTHERAPY FOR POSTERIOR UVEAL MELANOMA. 61
28489707 2019
18
Long-Term Metastatic Risk after Biopsy of Posterior Uveal Melanoma. 61
29705056 2018
19
Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II. 61
30237818 2018
20
Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I. 61
30237817 2018
21
Scleral necrosis in patients with posterior uveal melanomas evaluated by transcleral fine needle aspiration biopsy and treated by 125I plaque. 61
29995126 2018
22
Predictors of anxiety and depression 2 years following treatment in uveal melanoma survivors. 61
29601654 2018
23
Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications. 61
29538180 2018
24
Unsuspected and misdiagnosed posterior uveal melanoma following enucleation and evisceration in Ottawa-Gatineau. 61
29631828 2018
25
Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses. 61
29789761 2018
26
Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma. 61
28444874 2018
27
Posterior uveal melanoma in adolescents and children: current perspectives. 61
30464381 2018
28
Comparison of Gene Expression Profiling and Chromosome 3 Analysis by Fluorescent in situ Hybridization and Multiplex Ligation Probe Amplification in Fine-Needle Aspiration Biopsy Specimens of Uveal Melanoma. 61
29344493 2017
29
[Diagnosis and Therapy of Iris Lesions]. 61
29156467 2017
30
Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management. 61
28756956 2017
31
IMAGE QUALITY AND ARTIFACTS ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY: Comparison of Pathologic and Paired Fellow Eyes in 65 Patients With Unilateral Choroidal Melanoma Treated With Plaque Radiotherapy. 61
27893622 2017
32
Comparison of Alternative Tumor Size Classifications for Posterior Uveal Melanomas. 61
28672400 2017
33
Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management. 61
28163118 2017
34
Repeat Episcleral Plaque Brachytherapy: Clinical Outcomes in Patients Treated for Locally Recurrent Posterior Uveal Melanoma. 61
28048976 2017
35
Independent Prognostic Significance of Gene Expression Profile Class and Largest Basal Diameter of Posterior Uveal Melanomas. 61
26596399 2016
36
[THE BRAF MUTATION AND THE POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION]. 61
27860480 2016
37
Clinical application of genetic testing for posterior uveal melanoma. 61
27847622 2016
38
Is it sufficient to repeat LINEAR accelerator stereotactic radiosurgery in choroidal melanoma? 61
27546698 2016
39
Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. 61
26160531 2015
40
American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7,731 Patients: The 2013 Zimmerman Lecture. 61
25813452 2015
41
Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland. 61
25853443 2015
42
Gene expression profiling and regression rate of irradiated uveal melanomas. 61
25856819 2015
43
Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. 61
25439609 2015
44
Frequency and implications of discordant gene expression profile class in posterior uveal melanomas sampled by fine needle aspiration biopsy. 61
25448994 2015
45
Regression rate of posterior uveal melanomas following iodine-125 plaque radiotherapy. 61
25624683 2015
46
The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma. 61
25537201 2014
47
Diffusion restriction of posterior uveal melanoma on MR imaging. 61
25597216 2014
48
Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. 61
24169649 2014
49
Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. 61
24463441 2014
50
Outcomes of iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy. 61
24462385 2014

Variations for Posterior Uveal Melanoma

Expression for Posterior Uveal Melanoma

Search GEO for disease gene expression data for Posterior Uveal Melanoma.

Pathways for Posterior Uveal Melanoma

Pathways related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 VEGFA TAP2 TAP1 BCL2
2
Show member pathways
12.56 VEGFA THBS2 THBS1 CCND2 BCL2
3
Show member pathways
12.49 TAP2 TAP1 CCND2 BCL2
4
Show member pathways
12.34 MITF CCND2 BRAF BCL2
5 12.28 VEGFA MITF CCND2 BRAF BCL2
6 12.16 VEGFA THBS1 CCND2 BCL2
7
Show member pathways
12.1 THBS1 CCND2 BCL2
8 12.02 VEGFA THBS1 BRAF
9 11.89 VEGFA CCND2 BRAF
10
Show member pathways
11.87 VEGFA THBS2 THBS1 CCND2 BRAF BCL2
11 11.82 VEGFA BRAF BCL2
12 11.61 THBS1 BRAF BCL2
13 11.44 THBS2 THBS1 TAP2 TAP1
14 11.3 VEGFA THBS1 BRAF
15 11.22 VEGFA BRAF
16 11.22 THBS2 THBS1
17 11.19 MITF BCL2
18 11.15 TAP2 TAP1
19 10.92 TAP2 TAP1
20 10.87 BRAF BCL2

GO Terms for Posterior Uveal Melanoma

Cellular components related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule GO:0031091 9.16 THBS2 THBS1
2 MHC class I peptide loading complex GO:0042824 8.96 TAP2 TAP1
3 TAP complex GO:0042825 8.62 TAP2 TAP1

Biological processes related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.76 VEGFA THBS1 CCND2 BCL2
2 positive regulation of cell migration GO:0030335 9.71 VEGFA THBS1 MIR182
3 positive regulation of gene expression GO:0010628 9.71 VEGFA MITF MIR182 BRAF
4 ovarian follicle development GO:0001541 9.55 VEGFA BCL2
5 pigmentation GO:0043473 9.52 MITF BCL2
6 sprouting angiogenesis GO:0002040 9.51 VEGFA THBS1
7 positive regulation of phosphorylation GO:0042327 9.49 VEGFA THBS1
8 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.48 TAP2 TAP1
9 melanocyte differentiation GO:0030318 9.43 MITF BCL2
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.43 VEGFA BRAF BCL2
11 peptide transport GO:0015833 9.37 TAP2 TAP1
12 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.32 TAP2 TAP1
13 vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane GO:1990668 9.16 TAP1 TAP2
14 negative regulation of apoptotic process GO:0043066 9.1 VEGFA THBS1 MITF CCND2 BRAF BCL2
15 cytosol to ER transport GO:0046967 8.96 TAP2 TAP1

Molecular functions related to Posterior Uveal Melanoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.61 VEGFA THBS2 THBS1
2 peptide antigen binding GO:0042605 9.49 TAP2 TAP1
3 extracellular matrix binding GO:0050840 9.48 VEGFA THBS1
4 fibronectin binding GO:0001968 9.46 VEGFA THBS1
5 MHC class I protein binding GO:0042288 9.4 TAP2 TAP1
6 MHC protein binding GO:0042287 9.37 TAP2 TAP1
7 TAP1 binding GO:0046978 9.32 TAP2 TAP1
8 MHC class Ib protein binding GO:0023029 9.26 TAP2 TAP1
9 peptide antigen-transporting ATPase activity GO:0015433 9.16 TAP2 TAP1
10 peptide transmembrane transporter activity GO:1904680 8.96 TAP2 TAP1
11 peptide-transporting ATPase activity GO:0015440 8.62 TAP2 TAP1

Sources for Posterior Uveal Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....